VYNE Therapeutics Announces Positive Biomarker Data For VYN201 In Vitiligo Study

Clinical-stage biopharma company VYNE Therapeutics Inc. (VYNE) Wednesday announced that its BET inhibitor had a positive effect on multiple disease-associated biomarkers in patients with non-segmental vitiligo.

Related Keywords

,Therapeutics Inc ,Vyne ,Dyne Therapeutics Inc ,